Neuro-Hitech Pharmaceuticals

Neuro-Hitech Pharmaceuticals was a biopharmaceutical company focused on the development and commercialization of therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company's lead candidate, Huperzine A, was a small molecule acetylcholinesterase inhibitor that reached Phase 2 clinical trials for the treatment of mild-to-moderate Alzheimer's. Through strategic acquisitions, including Q-RNA, MCR American Pharmaceuticals, and AMBI Pharmaceuticals, the company expanded its pipeline to include pre-clinical anti-amyloid and tau-targeting compounds, as well as a commercial portfolio of cough and cold products. Formerly publicly traded under the symbol NHPI, the company was acquired by Woodbrook Group in 2018.